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Abstract
Objectives: to evaluate mother-to-child transmission (MTCT) rates and related factors in HIV-infected pregnant
women from a tertiary hospital between 2000 and 2009.
Subjects and method: cohort of 452 HIV-infected pregnant women and their newborns. Data was collected from
recorded files and undiagnosed children were enrolled for investigation. Statistical analysis: qui-square test, Fisher
exact test, Student t test, Mann-Whitney test, ANOVA, risk ratio and confidence intervals.
Results: MTCT occurred in 3.74%. The study population displayed a mean age of 27 years; 86.5% were found to
have acquired HIV through sexual contact; 55% were aware of the diagnosis prior to the pregnancy; 62% were not
using HAART. Mean CD4 cell-count was 474 cells/ml and 70.3% had undetectable viral loads in the third trimester.
HAART included nevirapine in 35% of cases and protease inhibitors in 55%; Zidovudine monotherapy was used in
7.3%. Mean gestational age at delivery was 37.2 weeks and in 92% by caesarian section; 97.2% received intravenous
zidovudine. Use of AZT to newborn occurred in 100% of them. Factors identified as associated to MTCT were: low
CD4 cell counts, elevated viral loads, maternal AIDS, shorter periods receiving HAART, other conditions (anemia,
IUGR (intra uterine growth restriction), oligohydramnium), coinfecctions (CMV and toxoplasmosis) and the
occurrence of labor. Use of HAART for longer periods, caesarian and oral zidovudine for the newborns were
associated with a decreased risk. Poor adhesion to treatment was present in 13 of the 15 cases of transmission; in
7, coinfecctions were diagnosed (CMV and toxoplasmosis).
Conclusion: Use of HAART and caesarian delivery are protective factors for mother-to-child transmission of HIV.
Maternal coinfecctions and other conditions were risk factors for MTCT.
Introduction
Epidemiologic surveys show that HIV transmission pat-
terns have changed, shifting the epidemic towards the
poorer, those living in non-urban areas and women.
Increasing heterosexual transmission is responsible for
the ever growing rates of infected women. Considering
that 85% of infected women are within their reproduc-
tive years, the risk of mother-to-child transmission
(MTCT) is significant [1].
In Brazil, a sentinel study (Estudo Sentinela-Partur-
iente) has shown that the prevalence of HIV infection
among pregnant women is 0.41% and that HIV testing
for pre-natal care is performed in only 62.3% of patients
[2]. Out of 63 countries analyzed by UNAIDS, Brazil
provides antiretroviral therapy for 50 to 75% of infected
pregnant women [1]. MTCT rates were evaluated in a
large multicentric study that found 8.6% of newborn
infection in 2000 and 7.1% in 2001 [3].
Several factors have been implicated in MTCT of HIV,
including: advanced maternal AIDS-related illness, ele-
vated viral loads (VL), breastfeeding, route of delivery,
other infectious and obstetrics conditions and low CD4
cell counts during pregnancy [4-7]. Furthermore, viral
subtype [8], viral concentration in maternal genital fluids
[9,10] and genetic factors were also identified [11]. Short
duration of antiretroviral therapy during the course of
pregnancy, problems regarding adhesion to treatment
[12] and coinfecctions such hepatitis C virus [13], geni-
tal herpes [14], cytomegalovirus [15], syphilis [16],
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toxoplasmosis [17,18] and recreational drug abuse [19]
further increase the risk of MTCT.
The beneficial role of antiretroviral therapy in decreas-
ing the risk of MTCT of HIV has been largely docu-
mented, since ACTG 076 protocols were published [20].
The use of highly active antiretroviral therapy (HAART)
prior to conception and its earlier initiation in the
course of pregnancy was also associated with lower rates
of transmission [12].
CAISM/UNICAMP has been involved in the treat-
ment and care of HIV-infected pregnant women since
1988. A historical cohort of HIV infected pregnant
women has shown reduction of MTCT rates from
32.3% in 1990 to 2.9% in 2000. The greatest decline was
observed after the introduction of the complete recom-
mendations of ACTG 076 protocol. At that time, there
were no reported cases of MTCT in pregnant women
treated with HAART [21].
The objectives of this study were to evaluate mother-
to-child transmission of HIV and related factors, to
describe clinical and epidemiological profile of HIV
infected pregnant women in a specialized prenatal care
facility from 2000 to 2009 and to identify possible con-
sequences of maternal infection to the newborn infant.
Subjects and method
Observational and analytical study, with a historical
cohort constituted by a population of 452 HIV-infected
pregnant women in the period of 2000 to 2009 receiving
care at the institution. The women were retrospectively
selected from clinical records and from the epidemiolo-
gic surveillance system. A specific form was developed
for data gathering and the EPINFO program was used
for data analysis. The following variables were analyzed:
epidemiologic characteristics of the women (age, formal
education, parity, planned pregnancy), clinical character-
istics (previous use of HAART, previous diagnosis of
HIV, CD4 cell count, viral load, regimens of antiretro-
viral treatment, maternal coinfecctions and gestational
problems) and characteristics of the newborn (birth
weight, birth length, Capurro, Apgar scores, neonatal
morbidity and use of oral zidovudine).
All newborns exposed to HIV were referred to the
Pediatric Immunodeficiency Service at the same Univer-
sity. In the few cases, where a final diagnosis of HIV
infection in the newborn was not possible due to loss of
follow up, the main caretaker was contacted by phone
or mail. Research protocol was previously approved by
the Institution Review Board (Project number 459/2004).
Statistical analysis was conducted regarding demo-
graphic and epidemiologic characteristics of the women,
prenatal care, use of antiretroviral therapy, delivery and
newborn. Data was analyzed through proportions distri-
butions and means, comparatively between groups of
HIV-infected and non-infected children. The specific
effect of several different interventions was analyzed
through their individual risk ratios (RR). Possible asso-
ciations between each variable were further tested with
qui-square test or Fisher’s exact test. The association
between continuous variables was tested through stu-
dent t test (parametric data), Mann-Whitney test (non-
parametric data) and ANOVA. The 95% confidence
interval and the level of significance of 0.05 were used.
Data was analyzed with the statistical program SAS ver-
sion 9.1.
The association between maternal and perinatal vari-
ables and MTCT was evaluated with qui-square test,
Fisher’s exact test and calculation of risk ratio and confi-
dence intervals to 95%. Multivariate analysis was per-
formed according to the COX model for proportional
risks (adjusted risk ratio). However, due to problem dur-
ing mathematical convergence related to the actual
absolute number of positive outcomes (mother-to-child
transmission events), results in this front could not be
measured.
The study protocol was approved by the Internal
Review Board (IRB) of the Center for Women’s Inte-
grated Healthcare (CAISM), Department of Obstetrics
and Gynecology, University of Campinas (UNICAMP)
and by the IRB of the School of Medical Sciences of the
same institution (approval letter #459/2004).
Results
Between 2000 and 2009, 26.668 deliveries occurred in
the institution and 452 were from HIV-infected preg-
nant women, corresponding to a prevalence of 1.69% of
all deliveries. Figure 1 shows excluded cases in the final
analysis, performed with 401 infants. Data referring to
multiple gestations were not replicated. The analysis
comprised 392 gestation events.
Characteristics of pregnant women, prenatal care and
delivery
The characteristics of pregnant women are presented in
Table 1. The majority of them (243 in 389-62.5%) was
not on antiretroviral therapy when they got pregnant.
Among women already using antiretroviral drugs, the
most common combination was two nucleoside reverse
transcriptase inhibitors (NRTI) and one protease inhibi-
tor (PI) or one non-nucleoside reverse transcriptase
inhibitor (NNRTI). Ninety percent of women (295 in
328) reported good adhesion (95% or more of all
HAART had been taken as prescribed, in two occasions)
to treatment during pregnancy [22].
The mean number of prenatal visits was 7 (ranging
from 1 to 18). Mean gestational age at the beginning of
prenatal care was 18.1 weeks (ranging from 3 to 38).
The majority of women (273 in 392-69.6%) presented at
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least one obstetric complication: preterm labor (14.5%),
intrauterine growth restriction (6.1%) and chronic or
gestational hypertension (5.1%) among others. Two hun-
dred ninety nine in 392 (76.3%) had also at least one
other infectious complication: bacterial vaginosis
(32.9%), urinary tract infection (27%) and papilomavirus/
intracervical neoplasia (22.7%) were the most prevalent.
Resistance testing was performed only in 14 of 392
pregnant women (3.6%) by clinical indication (good
adhesion and elevated viral load after two months of
therapy). These patients were found to be carrying mul-
tiresistant HIV.
Prophylactic antiretroviral therapy (maternal CD4 >
350 for naive) was used in 39.1% (137 in 350). Only ele-
ven in 392 women (2.8%) did not use antiretroviral ther-
apy during pregnancy by late diagnosis; 41 in 384 (10.5%)
were exposed to efavirenz. Zidovudine monotherapy was
used by 28 in 384 women (7.3%) and in 21 patients, it
was maintained until birth. ART combinations used are
presented in Table 2. Mean CD4 cell-count was 474
cells/ml. Mean duration of antiretroviral therapy during
pregnancy was 142.4 days. After HAART with PI, 66
pregnant women (71.7%) had undetectable viral loads.
Three hundred and seventy in 380 cases (97.4%), intrave-
nous zidovudine was used during labor and delivery.
Mean gestational age at birth was 37.2 weeks. In 92%
(357 in 388) of cases, delivery was conducted by caesar-
ean section, mainly indicated by HIV infection.
Characteristics of the newborns
Of 401 newborns, 208 (52.9%) were female. Mean birth
weight was 2820 g and mean birth age by the method of
Capurro was 37.6 weeks. Seventy nine children were
premature (24%) and 87 (21.96%) had low birth weight.
Neonatal use of oral zidovudine in the hospital was con-
firmed in 100% of cases.
Twenty one children presented with major congenital
malformations among 48 in 393 (12.2%) presenting with
any malformation: 9 cases of cardiac anomaly, 7 cases of
genital tract malformations and 5 cases of urinary tract
malformations. The remaining cases comprised minor
malformation such as supernumerary finger, auricular
appendage, among others.
Thirty four in 382 children (8.9%) presented at least
one other illness during neonatal period (12 cases of
pneumonia, 10 cases of hepatitis C, 6 cases of candidia-
sis and toxoplasmosis, 4 cases of cytomegalovirus infec-
tion, hepatitis B and urinary tract infection, 3 cases of
meningitis and sepsis, 2 cases of syphilis and one case of
rubella, varicela and tuberculosis).
Figure 1 Mother-to-child transmission in HIV pregnant women from 2000 to 2009.
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Factors associated with mother-to-child transmission of
HIV
MTCT of HIV occurred in this cohort in 3.74% of cases.
Risk factors identified for transmission were: low CD4
cell count, maternal AIDS-related illness, reduced time
on HAART, obstetric and infectious concurring
illnesses, presence of labor, neonatal coinfecctions, low
birth weight, newborns small for gestational age, fail to
complete postnatal prophylactic use of oral AZT and
maternal and newborn anemia.
Any concurring AIDS-related illness during prenatal
care enhanced the risk of transmission in around 5
times; maternal anemia (hemoglobin level under 11 g/
dl) increased the risk of transmission in 4 times and
also in cases of intrauterine growth restriction. Ovular
infection elevated the risk in more than 21 times; neuro-
toxoplasmosis by itself increased it in more than 7 times
(Table 3).
First CD4 cell count during prenatal care was different
among cases associated with transmission of HIV (219.1
cells/ml) and those not associated with it (480.9 cells/
ml) (p = 0.002). Values lower than 350 cells/ml
increased the risk of MTCT in more than 12 times
(Table 3).
During gestation, use of HAART constituted protec-
tive factor against MTCT of HIV, with difference attrib-
uted to the mean duration of use in days among cases
of transmission (93.2 days) and those without transmis-
sion (144.2 days) (p = 0.0121). HAART use for less than
15 days prior to delivery determined and increased risk
of transmission of more than 5 times (Table 3). The use
of antiretroviral drugs during pregnancy was not asso-
ciated with low birth weight (p = 0.0808) or premature
birth (p = 0.43).
Caesarean operation has shown protection in the
order of 80% against MTCT of HIV. In the other, deliv-
ery occurring after the onset of labor determined an
increased risk of almost 5 times for transmission of HIV
(Table 3).
Children who were considered to be small for gesta-
tional age had an increased risk of almost 5 times for
HIV infection. Mean values of birth weight was different
in cases of transmission of HIV (2416 grams) and those
without (2836 grams) (p = 0.0392). Low birth weight
was associated with an increase of 3 times or more in
the risk of transmission. Children who did not receive
oral zidovudine in the neonatal period had an increased
risk of acquiring HIV of more than 35 times. Neonatal
infections were significantly associated with mother-to-
child transmission of HIV. Toxoplasmosis increased the
risk in almost 24 times and cytomegalovirus infection in
more than 15 times (Table 4). Table 5 shows character-
istics of HIV infected newborn and table 6 shows the
mother-to-child-transmission rate year by year. The ten-
dency is to a lower rate in the last years.
Discussion
The present study, analyzing 452 pregnancies from 2000
to 2009, found an HIV MTCT rate of 3.74%, which was
above the expected for a reference maternity, in which
Table 1 Characteristics of HIV-infected pregnant women




< 20 35 8.9
20 a 29 234 59.7
≥ 30 123 31.4
Caucasian race 234 59.7
Number of pregnancies
1-2 177 45.2
≥ 3 215 54.9
Fixed sexual partner 263 76.9
Planned pregnancy 73 21.8
Use of contraceptive method 214 62.9
Previous HIV-infected child 30 10.6
HIV diagnosis
Before pregnancy 215 55.1
During pregnancy 170 43.6





Not classified 54 13.9
First CD4 > 350 cel/ml (for NAIVE) 137 39.1
VL < 50(copies/ml) after HAART 93 53.1
Efavirenz exposition 41 10.5
Total 392 100
(#) The numbers are different because of lack of informations from some
patients
Table 2 Association between HAART combinations during
pregnancy and newborn infection
Newborn infection With Without P* RR IC 95%
N % n %
Antiretroviral therapy 0.0478
AZT Monotherapy 3 14.3 18 85.7 1.00
NRTI+NRTI 0 0.0 14 100 NC
NRTI+NRTI+NVP 5 3.9 124 96.1 0.27 0.07-1.05
NRTI+NRTI+NFV 3 2.3 125 97.7 0.16 0.04-0.63
NRTI+NRTI+LPV/R 1 1.6 63 98.4 0.11 0.01-0.99
Other PI regimens 1 4.3 22 95.7 0.30 0.03-2.70
(#) Missed information for 13 cases in 392 gestation events
(##) NC: not calculated
(###) No antiretroviral: 11 cases; 2 cases with newborn infection
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nationally [23] and internationally accepted standard
prophylactic measures are routinely employed in the
care of HIV infected pregnant women. However, further
studying of the 15 cases of transmission of HIV has
shown particular results that explain such numbers. In
spite of a multidisciplinary approach to prenatal care,
with emphasis in medical (infectious disease specialist
and obstetrician) and psychosocial care, the vast major-
ity of mothers had substantial problems regarding adhe-
sion to treatment and regular use of antiretroviral
therapy prescribed during the gestation period. As a
direct consequence of poor adhesion to treatment, some
women reached delivery bearing high viral loads or even
unknown values of viral load.
Our results shown several risk factors (low CD4 cell
count, maternal AIDS-related illness, reduced time on
HAART, obstetric and infectious concurring illnesses,
presence of labor, neonatal coinfecctions, low birth
weight, newborns small for gestational age, fail to com-
plete postnatal prophylactic use of oral AZT and mater-
nal and newborn anemia) associated with MTCT of
HIV, confirming worldwide data on the subject
[4-7,12,15,17,18].
Women with advanced degrees of imunossupression
(CD4 < 350 or AIDS) had a significantly higher risk of
transmitting HIV to their newborns, similarly to results
found in literature [4-7,24].
HAART leads to undetectable viral load more rapidly
in the course of treatment [12,25-27]. HAART in com-
parison to AZT monotherapy was strongly associated
with decreased risk of MTCT. Duration of antiretro-
viral therapy shorter than 15 days was associated with





P* RR IC 95%
N % n %
AIDS-related illness 0.0748
Yes 2 14.3 12 85.7 4.87 1.19-19.93
No 11 2.9 364 97.1 1.00
First CD4 (cel/ml) 0.0029
≥ 350 1 0.5 212 95.5 1.00
< 350 8 5.8 129 94.2 12.44 1.57-98.35
Time using HAART 0.0632
15 days or longer 11 3.1 342 96.9 1.00
Less than 15 days 2 16.7 10 83.3 5.35 1.33-21.53
Ovular infection 0.0035
Yes 2 66.7 1 33.3 21.61 8.15-57.29
No 12 3.1 377 96.9 1.00
Neurotoxoplasmosis 0.0127
Yes 1 25 3 75 7.46 1.26-44.23
No 13 3.4 375 96.6 1.00
Route of delivery 0.0190
Vaginal 4 12.9 27 87.1 1.00
Caesarean 10 2.8 347 97.2 0.22 0.07-0.65
Labor 0.0088
Yes 6 9.8 55 90.2 4.54 1.58-13.04
No 7 2.2 316 97.8 1.00
Time after ruptured membranes 0.5936
Less than 4 hours 2 11.1 16 88.9 1.00
> 4 hours 3 8.1 34 91.9 0.73 0.13-3.99
No 10 328
IV AZT 0.3126
Yes 12 3.5 362 96.5 0.35 0.05-2.40
No 1 10.0 9 90 1.00
Anemia (Hb level < 11 g/dl) 0.0254
Yes 4 11.8 30 88.2 4.21 1.40-12.72
No 10 2.8 348 97.2 1.00
(#) The numbers are different because of lack of informations from some patients
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and increased risk, as was demonstrated by interna-
tional study [12]. It is established that after two weeks
of antiretroviral therapy the decrease in maternal viral
load would be sufficient to decrease the risk of neona-
tal infection. Our data found that PI containing regi-
mens were an important factor to protect against
MTCT.
Preterm and low birth weight were not observed as
complications of HAART use during pregnancy, in
agreement with findings of other studies [28-31], but as
opposite to what was concluded by others [32-34].
Thus, our results confirm the safety of antiretroviral
drugs during pregnancy.
Obstetric and infectious complications of pregnancy
have also lead to an increase in the risk of newborn
HIV infection, in particular: anemia, intrauterine growth
restriction and ovular infection. These factors can be
symptomatic of compromised placental barrier function,
increasing its permeability to HIV [35] and corroborate
the importance of referring prenatal care of HIV
infected pregnant women to tertiary specialized health-
care centers.
Table 4 Neonatal factors associated with mother-to-child transmission of HIV
VARIABLES With Without P* RR IC 95%
N % n %
Birth weight 0.0270
≥ 2500 g 8 2.8 301 97.2 1.00
< 2500 g 7 8.0 80 92 3.11 1.16-8.33
Birth Weight in comparison to gestational age (GA) 0.0110
Adequate forGA 10 2.9 332 97.1 1.00
Small for GA 5 13.2 33 86.8 4.50 1.62-12.48
Oral AZT 0.0010
Yes 11 2.8 381 97.2 1.00
No 2 100 0 0 35.64 19.90-63.81
Neonatal pathology 0.0047
Yes 5 14.7 29 85.3 5.67 2.01-15.96
No 9 2.6 338 97.4 1.00
Congenital Toxoplasmosis < 0.0001
Yes 4 66.7 2 33.3 23.94 10.63-53.93
No 11 2.8 384 97.2 1.00
Pneumonia 0.0076
Yes 3 25.0 9 75 8.10 2.63-25.02
No 12 3.1 377 97.9 1.00
Congenital CMV 0.0075
Yes 2 50.0 2 50 15.27 5.00-46.63
No 13 3.3 384 96.7 1.00
Hepatitis B 1.0000
Yes 0 0.0 4 100 NC
No 15 3.8 382 96.2
Syphilis 1.0000 NC
Yes 0 0.0 2 100
No 15 3.8 384 96.2
Anemia (hb < 13,5 g/dl) 0.0051
Yes 8 8.7 84 91.3 5.83 1.58-21.46
No 3 1.5 198 98.5 1.00
IUGR (intra uterine growth restriction) 0.0470
Yes 3 12.5 21 87.5 4.18 1.25-14.00
No 11 3.0 357 97 1.00
Hepatitis C 1.0000
Yes 0 0.0 10 100 NC
No 15 3.8 376 96.2
(#) The numbers are different because of lack of informations from some patients
(##) NC: not calculated
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01 00 10 < 100 - - AZT 112 No Yes No 0 Ces No 41 3370 No PCP Yes
02 00 - - - - AZT 49 No Yes Yes 2 h Vag Yes 36 2530 No Toxo No
03 00 2 - - - AZT 40 No Yes Yes 0 Ces Yes 40 3110 No Rubella No
04 01 8 - - - AZT 21 No Yes Yes 0 Ces No 38 3230 No No No
05 01 3 289 - - Haart 14 No Yes No 0 Ces No 34 2635 No No No
06 01 9 11 05 47000 Haart 260 No Yes Yes 1 h Vag Yes 37 1985 Candid, PCP Toxo Yes
07 02 6 315 - 420 AZT 10 No Yes Yes 240 h Vag Yes 33 1320 Stevens-Johnson,
Hep C
No No
08 02 3 110 - 17000 Haart 255 No Yes Yes 0 Ces No 40 3000 Neurotox Toxo No
09 03 5 344 - < 50 Haart 140 Yes Yes Yes 0 Ces Yes 40 3695 No No Yes
10 04 6 424 630 1410 Haart 84 No Yes Yes 0 Ces No 35 1340 No Oral cand. No
11 04 5 233 - - AZT 135 No Yes No 0 Ces No 33 1705 No CMV No
12 05 0 - - - No 0 No No No 63 h Vag Yes 32 1425 No No No
13 06 2 160 - - Haart 21 No Yes Yes 0 Ces Yes 39 2790 No No No
14 06 1 135 120 38380 Haart - No Yes Yes 7 h Ces Yes 37 2015 No First gemelar No



















Great controversy still exists regarding the route of
delivery in HIV infected pregnant women. Micro trans-
fusions occurring during uterine contractions enhance
blood exchanges between mother and fetus and the pre-
sence of significant viral load becomes an important fac-
tor in newborn HIV infection. Another issue presents
itself as plasma viral load does not adequately represent
viral concentrations in vaginal fluids [9]. So, even
patients with sustained undetectable plasma viral load
could still carry substantial viral load in vaginal secre-
tions. Our data pointed out that the presence of labor
has significantly increased the risk of MTCT.
This study demonstrated also, in concordance to cur-
rent literature, a lower rate of MTCT following elective
caesarean delivery, including women on potent antire-
troviral therapy and with low peripartum plasma viral
load [25,36]. In fact, this has been the standard of care
in this healthcare facility since 2005, provided that the
patient did not present in advanced labor (elective cae-
sarean delivery). Previous studies discussed the higher
post partum morbidity in HIV pregnant women sub-
mitted to a caesarean section. However, recent studies
did not find this association, leading to a relative safety
by performing a caesarean in these women [25].
Premature rupture of membranes followed by vaginal
delivery was present in one case of newborn infection,
confirming it as a collaborating factor for MTCT
[24,35].
Low birth weight and small for gestational age also
had increased risk for MTCT [37]. Among 15 infected
newborns, in seven cases low birth weight was a contri-
buting factor. Furthermore, several of these presented
with serious infectious complications of the neonatal
period. Maternal acute infections can compromise
placental barrier, increasing the risk of MTCT. Several
studies have demonstrated association, especially with
maternal toxoplasmosis [17,18] and CMV [15], reinfor-
cing the need of exhaustive screening of these infections
during prenatal care. Co-infection with hepatitis C
occurred in more than 10% of cases, which can also
enhance transmission of HIV [13].
There was one case of multiple gestation in which
only the first to be born was infected. Although there is
no known association between MTCT and multiple
pregnancies after the use of HAART, the first newborn
is more frequently infected [38].
Postnatal prophylaxis with oral zidovudine has
demonstrated to be a significant factor in protection
against neonatal HIV infection since ACTG 076 proto-
col [20], and our findings were similar.
This study demonstrates that MTCT was strongly
associated with maternal factors such as the stage of
HIV infection, represented by CD4 counts and viral
load, use of HAART and route of delivery, and also fac-
tors regarding the gestational period, especially the pre-
sence of maternal infectious and obstetric
complications. Regarding the newborn, use of neonatal
zidovudine still poses as an important factor in the pro-
tection against HIV transmission.
One limitation of this study was the impossibility of
multivariate analysis due to a limited number of infected
newborns, which led us to interpretations based solely
on risk ratios.
The increasing number of women infected with HIV
observed over the past few years alerts to the impor-
tance of approaching the issue of MTCT as a serious
public health problem. As a direct consequence of this
are the emotional losses to these families and also the
considerable financial expenses to both the public and
private health system for the care and management of
an incurable infection.
Our data demonstrate a high rate of MTCT. However
it is strongly associated with poor adhesion to treatment
of both HIV and concurring illnesses, to the presence of
AIDS and other serious diseases. If only the cases in
which newborn infection was in fact preventable were
to be analyzed separately, it could be concluded that in
one single case such scenario was true, in which all
standard prenatal measures were implemented success-
fully leading to undetectable viral load prior to delivery.
The increasing number and complexity of cases
reduce the quality of psychosocial and clinical support
which, in turn, can influence adhesion to therapy and
eventually lead to poor outcomes to the newborn. Thus,
it becomes paramount for the HIV-infected pregnant
women to be referred to a tertiary care center offering a
multiprofessional approach aiming towards good
Table 6 Mother-to-child transmission of HIV by years of
birth
YEAR With Without total
N % n %
2000 3 13.6 18 86.4 22
2001 3 6.1 46 93.9 49
2002 2 3 65 97 67
2003 1 2.5 39 97.5 40
2004 2 3 40 97 42
2005 1 3.1 31 96.9 32
2006 2 4.4 44 95.7 46
2007 0 0 37 100 37
2008 1 1.9 51 98.1 52
2009 0 0 12 100 12
Total (#) 15 3.7 384 96.3 399
(#) The numbers are different because of lack of information from some
patients
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adhesion to treatment and, ultimately, reducing mother-
to-child transmission of HIV.
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